Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab.
Alvarez
J M
JM
Department of Cardiothoracic Surgery, Monash Medical Centre, Clayton, Melbourne, Australia.
D000077284:Abciximab; D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000191:economics / Q000379:methods*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000191:economics; D001026:Coronary Artery Bypass / Q000191:economics; D004630:Emergencies; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000191:economics*; D017722:Hospital Charges; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000191:economics; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000191:economics; D017713:Platelet Transfusion / Q000191:economics; D015607:Stents; D017211:Treatment Failure
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab